Imepitoin

Verify with FDA CVM →

193 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
193
Total Reports
2
Deaths Reported
100.0%
Death Rate

Active Ingredients

Imepitoin

Administration Routes

OralUnknown

Species Affected

Dog 193

Most Affected Breeds

Dog (unknown) 27
Retriever - Labrador 19
Dog (other) 14
Shepherd Dog - German 9
Retriever - Golden 9
Crossbred Canine/dog 9
Dachshund (unspecified) 8
Beagle 6
Cattle Dog - Australian (blue heeler, red heeler, Queensland cattledog) 6
Shih Tzu 6

Most Reported Reactions

Behavioural disorder NOS 28
Ataxia 23
Vomiting 22
Increased appetite 19
Aggression 17
Diarrhoea 13
Lethargy (see also Central nervous system depression in Neurological) 12
Decreased appetite 11
Drooling 11
Destructive behaviour 8
Elevated alanine aminotransferase (ALT) 8
Not eating 7

Outcome Breakdown

Recovered/Normal
120 (62.2%)
Outcome Unknown
70 (36.3%)
Euthanized
2 (1.0%)
Recovered with Sequela
1 (0.5%)

Data Summary

Metric Value
Total adverse event reports 193
Reports involving death 2
Case-fatality rate (reported events) 100.0%
Distinct species in reports 1
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Imepitoin Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 193 adverse event reports referencing Imepitoin, including 2 reports in which the animal died — a 100.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Imepitoin. Reported administration routes include Oral, Unknown. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Imepitoin reports are Dog (193 reports), with Dog accounting for the largest share. Within those species, Dog (unknown) (27), Retriever - Labrador (19), Dog (other) (14) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Imepitoin are Behavioural disorder NOS (28), Ataxia (23), Vomiting (22), Increased appetite (19). Of the 193 reports with a coded outcome, Recovered/Normal is the leading category at 62.2%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Imepitoin.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial